A CVID Trough That Used to Be Enough
Three years of a trough that once counted as adequate hasn't stopped two pneumonias and new bronchiectasis, testing whether the old IVIG target itself was ever right for this patient specifically.
Sofia N., 29, designs branding materials from a home office she built out of her spare bedroom, work she can mostly do around the fatigue and the days lost to sinus infections that have shaped her twenties more than she expected them to. She was diagnosed with common variable immunodeficiency at twenty-six, after years of recurrent sinusitis and two pneumonias that her doctors had chalked up to bad luck before anyone checked her immunoglobulin levels. She has been on monthly IVIG replacement at 400 mg/kg for three years, and her trough IgG has run steady around 520 mg/dL — a number that clears the roughly 400-500 mg/dL floor most older replacement guidance treats as adequate.
Adequate by that older standard hasn't meant infection-free. She has had two more pneumonias in the past year despite the steady trough, and a CT obtained after the second one showed early bronchiectasis — permanent airway damage that recurrent infection, not her underlying CVID directly, most plausibly caused. That finding reframes the actual question: whether 500 mg/dL was ever the right target for her specifically, rather than a population-level floor. Two 2010 papers bear on that directly, and they say different things. Orange and colleagues pooled seventeen studies and found pneumonia incidence falling by 27 percent for every additional 100 mg/dL of trough IgG, with no plateau across the studied range: at a maintained trough of 500 mg/dL the pneumonia rate was roughly five times what it was at 1,000. Lucas and colleagues, following ninety CVID patients at one center across twenty-two years, argued the opposite emphasis — that there is no single correct trough, that the effective level ranged from 5 to 17 g/L between individuals, and that the target should be set by whether a given patient stops getting infected rather than by a number. What makes that second paper the more pointed one for Sofia is its specific finding that patients with proven bronchiectasis required higher replacement doses than the rest of the cohort. She acquired hers this year, which moves her into that subgroup after three years of being dosed as though she were not in it.
A chest that has already sustained one round of structural damage from infection is more vulnerable to the next round, not equally vulnerable the way an undamaged chest would be — which is what makes this visit different from her prior three years of routine infusions, and the clinical argument for treating the trough target as something that should have moved the moment the CT came back, rather than waiting for a formal escalation conversation to happen on its own schedule.
When the trough that used to be enough stops being enough
I want to raise her target trough, not just her dose incrementally — target something closer to 800 mg/dL rather than the 500 she's been holding at. Orange and colleagues' 2010 meta-analysis put a number on it: 27 percent fewer pneumonias per 100 mg/dL of additional trough, and a five-fold difference in pneumonia rate between a trough held at 500 and one held at 1,000. And Lucas and colleagues, in the same year, found bronchiectasis specifically marked out the patients who needed more — which she now is, on top of two breakthrough pneumonias at a trough everyone used to call adequate. That's not a patient who needs reassurance that her number is technically in range; it's a patient whose number has already been shown, by her own last year, not to be protecting her.
I don't disagree with the direction, but I'd get there incrementally rather than in one jump.
Getting from a trough of 520 to one near 800 means something like a 50 to 60 percent increase in her monthly dose, not the doubling that gets quoted — but that is still a materially longer infusion and a real increase in infusion-reaction risk at that volume, and a cost jump insurers don't always approve on the first request without documented escalation. A stepwise increase — recheck trough and clinical status at each step — gets her to the same place without assuming the first big jump is automatically right for her specific pharmacokinetics, which vary meaningfully between patients even at the same weight-based dose.
Agreed: monthly IVIG dose increased in a stepwise fashion toward a target trough nearer 800 mg/dL rather than the prior 500 mg/dL floor, with trough and clinical status reassessed after each increase rather than jumping to the full target dose immediately.
Also raised, not yet decided: a switch to weekly subcutaneous immune globulin once her target trough is reached, which would let her spread the same total monthly dose across smaller, more frequent infusions she could eventually give herself at home rather than returning to the infusion center each month. She asked to try the current IV escalation first before adding a route change on top of a dose change.